RhumbLine Advisers
PCVX icon

RhumbLine Advisers’s Vaxcyte PCVX Stock Holding History

RhumbLine Advisers’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.6M Sell
168,486
-31
-0% -$1.81K 0.01% 1090
2026
Q2 		$9.8M Buy
168,517
+9,676
+6% +$526K 0.01% 1110
2026
Q1 		$9.23M Buy
158,841
+7,922
+5% +$430K 0.01% 1094
2025
Q4 		$6.96M Sell
150,919
-32,293
-18% -$1.44M 0.01% 1232
2025
Q3 		$6.6M Sell
183,212
-15,275
-8% -$506K 0.01% 1287
2025
Q2 		$6.45M Buy
198,487
+17,257
+10% +$566K 0.01% 1282
2025
Q1 		$6.84M Buy
181,230
+9,416
+5% +$753K 0.01% 1202
2024
Q4 		$14.1M Buy
171,814
+7,711
+5% +$766K 0.01% 893
2024
Q3 		$18.8M Buy
164,103
+4,808
+3% +$433K 0.02% 750
2024
Q2 		$12M Buy
159,295
+11,001
+7% +$749K 0.01% 945
2024
Q1 		$10.1M Buy
148,294
+17,743
+14% +$1.23M 0.01% 1036
2023
Q4 		$8.2M Buy
130,551
+241
+0.2% +$12.5K 0.01% 1156
2023
Q3 		$6.64M Buy
130,310
+6,131
+5% +$302K 0.01% 1197
2023
Q2 		$6.2M Buy
124,179
+29,005
+30% +$1.37M 0.01% 1254
2023
Q1 		$3.57M Buy
95,174
+3,377
+4% +$143K ﹤0.01% 1510
2022
Q4 		$4.4M Buy
91,797
+23,567
+35% +$925K 0.01% 1354
2022
Q3 		$1.64M Buy
68,230
+6,682
+11% +$169K ﹤0.01% 1867
2022
Q2 		$1.34M Buy
61,548
+10,759
+21% +$249K ﹤0.01% 1989
2022
Q1 		$1.23M Buy
50,789
+3,852
+8% +$84.2K ﹤0.01% 2049
2021
Q4 		$1.12M Sell
46,937
-536
-1% -$12.5K ﹤0.01% 2162
2021
Q3 		$1.2M Buy
47,473
+2,127
+5% +$51.6K ﹤0.01% 2149
2021
Q2 		$1.02M Buy
45,346
+16,763
+59% +$343K ﹤0.01% 2238
2021
Q1 		$565K Buy
28,583
+6,186
+28% +$156K ﹤0.01% 2435
2020
Q4 		$595K Buy
22,397
+1,996
+10% +$74.2K ﹤0.01% 2368
2020
Q3 		$1.01M Buy
+20,401
New +$812K ﹤0.01% 1991

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Pivotal bioVenture Partners Investment Advisor
Pivotal bioVenture Partners Investment Advisor San Francisco, California $252M AUM 45.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return

RhumbLine Advisers's PCVX Position: Q3 2026 in Review

RhumbLine Advisers reduced its Vaxcyte (PCVX) stake by 0.02% in Q3 2026, selling an estimated $1.81K and leaving 168,486 shares worth $9.6M. The position accounts for 0.01% of the portfolio, ranked #1090.

RhumbLine Advisers first reported a position in PCVX in Q3 2020 and has held it in 25 quarters since. The position peaked at $18.8M in Q3 2024. 259 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • RhumbLine Advisers held 168,486 shares of Vaxcyte worth $9.6M as of Q3 2026.
  • RhumbLine Advisers sold 31 Vaxcyte shares in Q3 2026, an estimated $1.81K.
  • Vaxcyte made up 0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #1090 holding.
  • RhumbLine Advisers first reported a position in Vaxcyte in Q3 2020 and has held it in 25 quarters since.
  • RhumbLine Advisers's Vaxcyte position peaked at $18.8M in Q3 2024.
  • 259 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.